#ROBERT HUGIN TRIAL#

But during his reign the company swelled into the top 15 global tier, building a rep as one of the most prolific - and competent - dealmakers in biopharma.

Hugin’s old company Celgene also lost quite a bit of investor value in the 3 years since he stepped down, taking the chairman’s job for awhile.

Its 2019 guidance has disenchanted investors, further pummeling the company’s already battered stock price as the activists stepped up pressure on the leadership. I look forward to contributing to the board’s effective, independent oversight of Allergan’s strategy.Īllergan needs all the help it can get right now. In Allergan, I see a company with market leading positions in four therapeutic areas, a promising R&D pipeline and a focus on executing its business strategy. In the meantime, Hugin - who lost his bid (and a fortune) in a run for a New Jersey Senate seat last fall - was ready to put his shoulder to the wheel of investor value. For now, Saunders remains completely in charge, with the backing of his board. When will that next transition be? We don’t know. Before that, he was executive vice president and global head of hematology and oncology.(T)he Allergan Board of Directors today announced its intention to recommend FOR a pending shareholder proposal, which will also appear in Allergan’s 2019 proxy statement, requiring an Independent Board Chair to be phased in during the next leadership transition. Prior to becoming CEO in 2016, he was president and COO. On behalf of all Celgene employees, we wish Bob and his family the best in the next chapter of his life.”Īlles has been with Celgene since 2004. “Bob is an inspirational leader, a mentor and a friend to everyone associated with the organization. Under his stellar strategic leadership and guidance, Celgene has achieved unprecedented growth, produced extraordinary business results and, most importantly, has developed and delivered transformational therapies for patients,” Alles said. “Bob Hugin has contributed immeasurably to Celgene during his 19-year tenure. He was elected to serve on the board of directors in 2001 and became chairman in 2011. He then served as president and chief operating officer from 2006 to 2010, and CEO from 2010 until being named executive chairman in March 2016. Hugin joined the company in 1999 as chief financial officer. “I am thankful to my colleagues at Celgene, as well as to patient advocates, medical researchers and physicians across New Jersey and throughout the health care system for their collaboration in advancing this fundamentally important mission in the service of patients.” Facebook gives people the power to share and makes the world more open and connected. “It has been a tremendous privilege to be part of Celgene’s growth and to help advance Celgene’s mission to serve patients through scientific breakthroughs in the treatment of cancer and other serious medical conditions,” Hugin said. Join Facebook to connect with Robert Hugin and others you may know. Robert Hugin is chairman and CEO of Celgene, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies. Hugin, who retired as CEO of Celgene in 2016, is also stepping down from the company’s board of directors.Ĭelgene CEO Mark Alles has been named chairman, the company said. “I think a lot of people will be behind Bob if he decides to run,” Bill Palatucci, New Jersey’s Republican national committeeman, told Politico New Jersey’s Matt Friedman earlier this month. Hugin (Bob) is the Executive Chairman of Celgene Corporation, a biopharmaceutical company with operations in more.

#ROBERT HUGIN TRIAL#

Hugin could be a challenger for Robert Menendez’s seat, which is up this November. Menendez is facing a second trial on corruption charges this summer. Hugin’s future plans were not announced, though it has been widely speculated that a run for U.S. Robert Hugin is retiring as executive chairman of Summit-based Celgene Corp., effective next Monday.

Robert hugin